New drug combo tested for tough-to-treat cancers that resist current treatments
NCT ID NCT05438420
Summary
This study is testing whether adding an experimental drug called Q702 to an existing immunotherapy (pembrolizumab) can help control advanced cancers that have stopped responding to previous treatments. The trial will enroll 120 people with advanced esophageal, stomach, liver, or cervical cancers to check safety and see if the combination shrinks tumors. Participants will receive both drugs together to determine if this approach works better than current options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, South Korea
-
CHA Bundang Medical Center
Seongnam-si, South Korea
-
Norton Cancer Institute
Louisville, Kentucky, 40202, United States
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital
Seoul, South Korea
-
University of Southern California
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.